Earnings summaries and quarterly performance for Q32 Bio.
Executive leadership at Q32 Bio.
Board of directors at Q32 Bio.
Research analysts covering Q32 Bio.
Recent press releases and 8-K filings for QTTB.
Q32 Bio Sells ADX-097 to Akebia Therapeutics
QTTB
M&A
Guidance Update
New Projects/Investments
- Q32 Bio Inc. sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. on November 28, 2025.
- The transaction includes $12 million in upfront and guaranteed near-term milestone payments, consisting of $7.0 million received at signing, $3.0 million on the six-month anniversary, and $2.0 million upon the earlier of a milestone or the end of 2026.
- Q32 Bio is eligible to receive up to a total of $592 million in development, regulatory, and commercial milestones, plus tiered royalties up to a mid-teen percent of annual net sales.
- This sale is expected to extend Q32 Bio's cash runway into the second half of 2027.
- The company will now strategically focus on advancing bempikibart for alopecia areata.
Dec 1, 2025, 12:14 PM
Q32 Bio Reports Third Quarter 2025 Financial Results and Corporate Update
QTTB
Earnings
Guidance Update
New Projects/Investments
- Q32 Bio Inc. reported a net loss of $7.4 million, or $0.60 per share, for the third quarter ended September 30, 2025, an improvement from a net loss of $17.6 million, or $1.46 per share, for the same period in 2024.
- As of September 30, 2025, cash and cash equivalents totaled $49.0 million, which is anticipated to fund operations into 2027.
- Research and development expenses decreased significantly to $3.6 million for Q3 2025, down from $14.3 million in Q3 2024, mainly due to reduced bempikibart development costs and the discontinuation of the ADX-097 program.
- The company completed enrollment in Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart, increasing the trial size to 33 patients, with topline data expected in mid-2026.
Nov 13, 2025, 12:03 PM
Q32 Bio Reports Q3 2025 Financial Results and Clinical Trial Updates
QTTB
Earnings
New Projects/Investments
- Q32 Bio reported cash and cash equivalents of $49.0 million as of September 30, 2025, which are expected to provide a financial runway into 2027.
- For the three months ended September 30, 2025, the company reported a net loss of $7.4 million, or $0.60 basic and diluted net loss per share.
- The company completed enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial, increasing the trial size to 33 patients based on demand, with topline data readout expected in mid-2026.
- Emerging signs of clinical activity are being observed among early-enrolling patients in Part B, and preliminary pharmacokinetic data shows steady state drug concentration is achieved at least nine weeks earlier compared to Part A due to the inclusion of a loading regimen.
Nov 13, 2025, 11:59 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more